Genmab gains on cancer deal with J&J

Genmab A/S (CSE:GEN) jumped DKK10.90 (16%) to DKK78.75 on Thursday after granting Johnson & Johnson (NYSE:JNJ) exclusive, worldwide rights to develop and commercialize cancer product daratumumab ( HuM...